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Introduction
Over the last decade, DBS analysis has gained popularity 
for TDM because it’s a patient friendly sampling proce-
dure [1-4]. Additional advantages are prolonged sample 
stability, lower risk of  infections and transportation at 
ambient temperature [1-3,5]. These advantages may fa-
cilitate implementation of  TDM in different clinical set-
tings including resource limited areas. Patients will bene-
fit from DBS analysis but the analytical development and 
validation of  DBS methods is more complex compared 
to plasma or serum analysis. 
Additional validation parameters, like the effect of  the 
hematocrit (HT) and blood spot volume need to be eval-
uated. Drug substances may also interact with the blood 
matrix or with the DBS card, resulting in matrix related 
recovery effects. Unfortunately, official guidelines for val-
idation of  DBS are not available yet.  However, in recent 
literature, several interesting issues related to analytical 
DBS research have been discussed [1,6-12]. Ongoing re-
search and improved understanding of  the factors that 
influence DBS analysis results will ultimately result in 
well-founded guidelines for DBS analytical method val-
idation. This would be very helpful for daily practice but 
would also benefit patient safety because uniformity in 
method validation prevents potential pitfalls during val-
idation or method development and increase credibility 
of  assay results. 
Our aim is to discuss some relevant topics related to DBS 
development prior to development of  future guidelines 
on DBS development and validation.
The  influence  of  blood   hematocrit  value  on  an-
alytical  results.
It is well known that the HT may affect analytical results. 
The blood HT affects the blood viscosity and that in turn 
influences the formation of  a blood spot, which affects 
the analytical results. The preparation of  the target HT 
values for standards and quality control samples is of  
great importance and a recent study has shown that the 
best result was obtained by centrifuging blood, followed 
by removal or addition of  a calculated volume of  plasma 
to adjust the HT [7]. However, it is advised to let the 
prepared HT be measured in order to confirm the cor-
rect preparation. In addition, extraction efficiency may 
also be influenced by the HT and concentration of  the 
substance. It is important to investigate these influences 
before the analytical procedure can be implemented in 
routine patient care [13]. In daily practice, correction of  
analytical results for the HT value using a linear HT cor-
rection method is simple but may not always correct for 
all HT effects. In that case, a point-to-point relationship 
between recovery, HT and concentration may be more 
feasible. Recently, a DBS method for the determination 
of  the HT by potassium measurement was published 
[14]. However, most likely a second spot is required for 
the potassium measurement using an immunoanalyzer. 
This implies a significant amount of  work for the devel-
opment and measurement of  the HT value and subse-
quently for setting up the correction formula. When no 
HT correction is applied, the method validation should 
include a range that covers substance concentration and 
a HT of  the target population with the analytical re-
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sults within acceptable limits. The approach of  whole 
spot analysis or pre-cut disks will show no effects of  
the HT on the spot formation [15-18]. However, if  ex-
traction efficiency is affected by HT and concentration 
of  the substance, this effect cannot be compensated. In 
addition, the main advantage of  a procedure for partial 
spot DBS analysis is the ease of  self-sampling for the 
patient, which is more complicated and more prone to 
sampling errors when exact blood volumes have to be 
applied. However, if  a health care professional is per-
forming the dried blood spot procedure and extraction 
efficiencies are stable, a whole spot analysis or pre-
cut disks can be of  advantage to avoid the HT effect. 
The influence of  the matrix on DBS recovery
Some substances may be difficult to extract from the 
spotting card matrix or they may form complexes with 
the endogenous components present in the DBS matrix 
[8, 9]. The extraction efficiency may be influenced by dif-
ferent aspects like nature of  the DBS material, extraction 
conditions, HT and concentration of  the substance.
Although most analytical DBS procedures may (appar-
ently) show no interaction of  the analyte with the blood 
in the DBS card or with the DBS card matrix itself, some 
studies showed an altered analytical response. The re-
searcher should be aware of  these possible interactions 
in order to acknowledge them in an early stage of  the 
analytical method development. For example, iron from 
the blood interacts with rifampicin to form a complex 
[8]. Addition of  both deferoxamine and ethylenedi-
aminetetraacetic acid (EDTA) to the extraction solu-
tion was applied to form a complex with the iron and 
recovery of  rifampicin in the DBS extraction increased 
to approximately 100% [8]. Another study showed that 
the combination of  low HT and high drug concentration 
does not only affect the spot size but also negatively af-
fects the extraction recoveries [9]. An increased number 
of  hydrogen bond acceptors was associated with more 
affinity to form hydrogen bonds with the cellulose of  the 
DBS card, making the extraction less efficient. 
Sample dilution in DBS analysis
When DBS analysis is performed for the measurement 
of  trough levels, a sufficient linear range can easily be 
validated. For the analysis of  pharmacokinetic curves, the 
linear range should be large enough or a dilution protocol 
should be validated. Various types of  dilution protocols 
can be validated. The DBS extract can be diluted with ex-
traction solvent or blank extract. With this approach, the 
dilution can be performed after the concentration is mea-
sured above the linear range. The DBS can be extracted 
with a larger extraction volume, or a smaller diameter can 
be punched and extracted with the original extraction 
volume. However, for both approaches, the concentra-
tion should be expected to be above the linear range be-
forehand. Including a smaller punch diameter in addition 
to the standard punch size during validation could also be 
an option for spots that would otherwise be too small for 
analysis and would be rejected. 
Measuring endogenous substances with DBS
In order to make DBS analysis even more patient friend-
ly, the analysis of  multiple substances in a single DBS 
extract would be preferred. This could include exoge-
nous and endogenous substances, like for example the 
additional analysis of  creatinine. For the measurement 
of  endogenous substances in DBS, the preparation of  
calibration standards and quality control samples pose a 
challenge, because it is impossible to obtain an analyte 
free matrix without changing the matrix itself. Changing 
the matrix by washing the red blood cells will have sig-
nificant effects on the formation of  the blood spot and 
gives possible other interactions with the blood matrix 
and DBS card.
A recent publication describing the validation of  creat-
inine in DBS addressed this issue by using three differ-
ent validation strategies; a 7-point calibration curve using 
the intercept of  the calibration to correct for the natural 
presence of  the creatinine in reference samples; a one 
point calibration curve at an extremely high concentra-
tion in order to diminish the contribution of  the natural 
presence of  creatinine and the use of  creatinine-[2H3] 
with an eight-point calibration curve [19]. 
Analytical vs clinical validation
In order to implement DBS analysis in daily practice, 
clinical validation studies need to be performed cap-
turing the variability that was not included during ana-
lytical validation. During clinical validation the overall 
results from the DBS procedure should be compared 
with conventional sampling. Till today no consensus 
has been reached for the number of  patients to in-
clude in a clinical validation. Numbers of  10 to 50 
have been mentioned in literature. Appropriate statisti-
cal tests should be used to compare results from DBS 
analysis and conventional blood sampling. To date, the 
most applied tests are Bland Altman analysis, Deming 
regression and Passing and Bablok regression [20-22].
Foreseeing daily routine, it seems important to have strict 
criteria considering the punching procedure (full and par-
tial spot analysis) and type of  DBS card, because these 
differences require a full validation during analytical de-
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velopment. In addition, assessment of  sample stability 
during ‘real life’ storage and shipment of  samples, could 
be evaluated by sending QC samples to the sampling 
environment for execution of  the routine procedures 
followed by re-sending the QC samples to the reference 
lab.  For best implementation of  the procedures, person-
al DBS sampling instructions should be performed and 
they should be available in a flyer and a video. 
To summarize 
The DBS analytical procedures are influenced by param-
eters like concentration range, HT value, matrix interac-
tions and patient population. Consequently, the valida-
tion parameters should be adjusted to the specific patient 
population. The HT can be set at the mean HT of  the pa-
tient population and prepared appropriately as discussed 
before. QC samples can be set at therapeutic concentra-
tions for trough levels and are used to assess the HT effect 
and recovery.  The more restricted framework of  param-
eters may show far less effects of  the HT and the com-
bination of  HT and concentration dependent recovery. 
The approach of  the restricted framework may make the 
analysis of  an extra DBS for HT assessment unnecessary 
and will create a more efficient workflow in the laboratory.
The use of  DBS for TDM is very promising, but there 
are several additional parameters compared to plasma 
analysis that should not to be underestimated and need 
to be considered before performing patient analyses. 
To conclude, the gained knowledge for analytical DBS 
development and validation has certainly evolved to a 
higher level but has not yet reached its final stage. An 
official guideline developed by scientific societies which 
is periodically updated would be useful for the field of  
DBS analysis. 
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